<DOC>
	<DOC>NCT00625521</DOC>
	<brief_summary>Lupus Erythematosus (LE) is an autoimmune disorder that includes a broad spectrum of clinical forms. One of these forms, Discoid Lupus Erythematosus (DLE) is a chronic disfiguring disease confined to the skin. The aim of this pivotal trial is to investigate the efficacy and safety of ASF-1096 cream 0.5% in the treatment of patients with DLE or SLE presenting newly developed discoid lesions.</brief_summary>
	<brief_title>Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<mesh_term>Lupus Erythematosus, Discoid</mesh_term>
	<criteria>A clinical diagnosis of either DLE or SLE Histological results from biopsy confirming the diagnosis (biopsy can be taken at screening) Is prepared to grant authorised persons access to the medical records Has signed informed consent Has an active skin disease other than DLE or another progressive or serious disease that interferes with the study outcome Has scarring at the target lesion Systemic treatment of SLE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Discoid lupus erythematosus</keyword>
</DOC>